Home PI3K/Akt/mTOR DNA-PK

DNA-PK Inhibitors

Cat.No. Product Name Information Product Use Citations Product Validations
S8427 LTURM34 LTURM34 is a specific DNA-PK inhibitor, 170-fold more selective for DNA-PK activity compared to PI3K activity, with IC50 value of 0.034 μM.
Front Oncol, 2023, 13:1287444
Int J Mol Sci, 2021, 22(19)10512
S6506 Compound 401 Compound 401 is a synthetic inhibitor of DNA-PK(IC50=0.28 μM) and mTOR (IC50=5.3 μM). It has no inhibition on p110α/p85α PI3K (>100 μM) and blocks the phosphorylation of S6 kinase 1 Thr389 and Akt Ser473 in COS7 cells.
Free Radic Biol Med, 2024, 224:831-845
S2758 Wortmannin (SL-2052) Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Nat Commun, 2025, 16(1):1313
EMBO J, 2025, 10.1038/s44318-025-00507-z
EMBO Mol Med, 2025, 10.1038/s44321-025-00222-6
Verified customer review of Wortmannin (SL-2052)
S1038 PI-103 PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM. This compound induces apoptosis in murine T-cell Lymphoma.
Nat Commun, 2025, 16(1):4828
Cell Rep, 2025, 44(5):115675
Genes (Basel), 2025, 16(8)892
Verified customer review of PI-103
S2871 T0070907 T0070907 is a potent inhibitor of PPARγ (peroxisome proliferator activator receptor γ ) that induces G2/M arrest and enhances the effect of radiation in human cervical cancer cells through mitotic catastrophe. It also acts as an antagonist of PPARγ that suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms.
Nucleic Acids Res, 2025, 53(14)gkaf669
Cell Rep Med, 2025, 6(10):102373
Apoptosis, 2025, 30(5-6):1391-1409
Verified customer review of T0070907
S1205 PIK-75 HCl PIK-75 HCl is a p110α inhibitor with IC50 of 5.8 nM (200-fold more potently than p110β), isoform-specific mutants at Ser773, and also potently inhibits DNA-PK with IC50 of 2 nM in cell-free assays.
Proc Natl Acad Sci U S A, 2025, 122(13):e2426929122
Mol Oncol, 2024, 10.1002/1878-0261.13716
Cancers (Basel), 2024, 16(2)370
Verified customer review of PIK-75 HCl
S8322 Samotolisib (LY3023414) Samotolisib (LY3023414, GTPL8918) is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK.
Elife, 2025, 13RP95952
Mol Oncol, 2024, 10.1002/1878-0261.13703
Cancers (Basel), 2024, 16(20)3520
Verified customer review of Samotolisib (LY3023414)
S2622 PP121 PP-121 is a multi-targeted inhibitor of PDGFR, Hck, mTOR, VEGFR2, Src and Abl with IC50 of 2 nM, 8 nM, 10 nM, 12 nM, 14 nM and 18 nM, also inhibits DNA-PK with IC50 of 60 nM.
Life Sci Alliance, 2021, 4(2)e202000882
PLoS One, 2016, 11(10):e0164895
Biochem Biophys Res Commun, 2015, 465(1):137-44
Verified customer review of PP121
S8589 SF2523 SF2523 is a highly selective and potent inhibitor of PI3K with IC50 values of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for PI3Kα, PI3Kγ, DNA-PK, BRD4 and mTOR, respectively.
Mol Ther Nucleic Acids, 2023, 31:309-323
Cell Biol Int, 2022, 10.1002/cbin.11833
Oncotarget, 2017, 8(58):98471-98481